Pharming’s Portfolio Grows As Ultra-Rare Disease Drug Joenja Is Approved
Priced At $547,500 Per Year
The first ever approval for ultra-rare immunodeficiency disease APDS gives Pharming its second product on the market but patient diagnosis will be a major challenge.
